ALXO
ALX Oncology Holdings Inc.
There isn't enough reported data to score ALXO yet.
ALXO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ALXO's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ALXO PE Valuation
ALXO has no meaningful PE right now: it lost money over the past year.
ALXO Forward outlook
There aren't enough analyst estimates for ALXO to show an outlook.
ALXO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.13 | +$1.05 |
| Q1 2026 | -$1.49 | +$0.96 |
| Q4 2025 | -$1.90 | +$0.68 |
| Q3 2025 | -$2.01 | +$0.96 |
| Q2 2025 | -$2.18 | +$1.45 |
| Q1 2025 | -$2.45 | +$1.26 |
| Q4 2024 | -$2.58 | +$1.16 |
| Q3 2024 | -$2.97 | +$0.60 |
ALXO is still losing money, but far less than before: $1.13 per share over the past year, against $3.74 at its worst in late 2023.
ALXO Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | -2047% | N/A |
| Q1 2020 | -800% | N/A |
| Q4 2019 | -638% | N/A |
| Q3 2019 | -242% | N/A |
ALXO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$16.1M | +$7.4M |
| Q1 2026 | -$18.7M | +$6M |
| Q4 2025 | -$19M | +$13.1M |
| Q3 2025 | -$17.1M | +$8.4M |
| Q2 2025 | -$23.5M | +$3.2M |
| Q1 2025 | -$24.7M | +$13.3M |
| Q4 2024 | -$32.1M | +$7.7M |
| Q3 2024 | -$25.5M | +$4.3M |
ALXO has burned cash in almost every quarter: −$71M over the past year, against −$106M the year before.
ALXO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +30% | +31.1M shares |
| 1 year | +154% | +82.3M shares |
| 3 years | +232% | +94.8M shares |
| 5 years | +239% | +95.6M shares |
| Available history | +518% | +114M shares |
ALXO has 136M diluted shares, up 154% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
ALXO Net Leverage
ALXO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALXO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.3 | Neutral |
| Stochastic | 22.2 | Neutral |
ALXO's weekly RSI is 34 (neutral) and its Stochastic is 22 (neutral).
ALXO PE vs Healthcare Sector
ALXO has no meaningful PE right now: it lost money over the past year.
ALXO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.18 | 8.5% below |
| 20 week MA | $1.67 | 35% below |
| 50 week MA | $1.73 | 38% below |
| 100 week MA | $1.38 | 22% below |
| 200 week MA | $4.50 | 76% below |
ALXO is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
ALXO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.0 | $88.6 | +195% |
| 2021 | $88.6 | $23.3 | -74% |
| 2022 | $23.3 | $11.1 | -52% |
| 2023 | $11.1 | $14.9 | +34% |
| 2024 | $14.9 | $1.62 | -89% |
| 2025 | $1.62 | $1.33 | -18% |
| 2026 YTD | $1.33 | $1.08 | -19% |
ALXO's yearly returns have swung widely, from +195% in 2020 to −89% in 2024. It's down 19% so far in 2026.